All In MedTech

FDA Clearance Tracker · P010019-S001

FOCUS NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 5, 2002 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 5, 2002

Approved

Time to decision

91 days

Received Apr 5, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P010019-S001
Device name
FOCUS NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES
Applicant location
Fort Worth, TX
Received
Apr 5, 2002
Decided
Jul 5, 2002
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Postapproval Study Protocol
Original approval
P010019

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE REVISED POST-APPROVAL STUDY PROTOCOL FOR THE DEVICE. THE POST-APPROVAL STUDY PROTOCOL WAS SUBMITTED TO COMPLY WITH THE CONDITIONS OF APPROVAL OUTLINED IN THE OCTOBER 11, 2001 APPROVAL ORDER FOR P010019.

Source documents

Other decisions for Alcon Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.